Nuveen
JANX icon

Nuveen’s Janux Therapeutics JANX Stock Holding History

Nuveen’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49M Hold
97,120
– – ﹤0.01% 2732
2026
Q1 		$1.35M Buy
97,120
+704
+0.7% +$9.65K ﹤0.01% 2432
2025
Q4 		$1.33M Buy
96,416
+787
+0.8% +$18.5K ﹤0.01% 2470
2025
Q3 		$2.34M Sell
95,629
-346
-0.4% -$8.43K ﹤0.01% 2241
2025
Q2 		$2.22M Sell
95,975
-27,704
-22% -$730K ﹤0.01% 2258
2025
Q1 		$3.34M Sell
123,679
-4,068
-3% -$153K ﹤0.01% 2125
2024
Q4 		$6.84M Sell
127,747
-39,145
-23% -$2.07M ﹤0.01% 1824
2024
Q3 		$7.58M Sell
166,892
-230,014
-58% -$10M ﹤0.01% 1773
2024
Q2 		$16.6M Buy
396,906
+318,281
+405% +$14.9M ﹤0.01% 1251
2024
Q1 		$2.96M Sell
78,625
-2,949
-4% -$64.2K ﹤0.01% 2215
2023
Q4 		$875K Buy
81,574
+14,872
+22% +$129K ﹤0.01% 2796
2023
Q3 		$672K Buy
66,702
+7,957
+14% +$91.8K ﹤0.01% 2736
2023
Q2 		$697K Buy
58,745
+12,842
+28% +$172K ﹤0.01% 2816
2023
Q1 		$555K Sell
45,903
-14,814
-24% -$247K ﹤0.01% 2785
2022
Q4 		$799K Sell
60,717
-12,160
-17% -$178K ﹤0.01% 2763
2022
Q3 		$987K Sell
72,877
-1,996
-3% -$26.7K ﹤0.01% 2758
2022
Q2 		$915K Buy
74,873
+49,213
+192% +$583K ﹤0.01% 2825
2022
Q1 		$392K Buy
25,660
+6,203
+32% +$101K ﹤0.01% 3071
2021
Q4 		$345K Hold
19,457
– – ﹤0.01% 3147
2021
Q3 		$421K Buy
+19,457
New +$560K ﹤0.01% 3200

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Nuveen's JANX Position: Q2 2026 in Review

Nuveen held its Janux Therapeutics (JANX) position steady in Q2 2026 at 97,120 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #2732.

Nuveen first reported a position in JANX in Q3 2021 and has held it in 20 quarters since. The position peaked at $16.6M in Q2 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Nuveen held 97,120 shares of Janux Therapeutics worth $1.49M as of Q2 2026.
  • Nuveen left its Janux Therapeutics share count unchanged in Q2 2026.
  • Janux Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2732 holding.
  • Nuveen first reported a position in Janux Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Nuveen's Janux Therapeutics position peaked at $16.6M in Q2 2024.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.